Rick Weddle: Welcome to “Site Selection Matters” where we take a close look at the art and science of site selection decision making. I’m your host, Rick Weddle, president of the Site Selectors Guild. In each episode, we introduce you to the top leaders in the world of corporate site selection and economic development. We speak with members of the guild, our economic development partners, and corporate decision-makers to provide you with deep insight into the best and next practices in our profession.
In this episode, we have as our guest, Bob Hess, vice chairman for global strategy with Newmark. In this capacity, Bob is team leader for their global business and real estate practice, and he’s responsible for strategy development, quality assurance, business development, and overall client service.
Today, Bob will talk with us about life sciences, an industry he’s conducted many site selection efforts for, and why it is a top targeted sector among scores of metros, ecosystems, corridors, and even countries around the world. Join me as we welcome Bob Hess to “Site Selection Matters.”
Bob, ever since the human genome was mapped, many different forms, or functions, or segments of life science have really become top of mind in economic development. Take a minute, if you will, and explain to our listeners exactly what we mean by life sciences and economic activity.
Bob Hess: Thanks, Rick. Yeah. Life science is such a dynamic innovation — I’ll call it growth industry — that everybody wants to participate in. And here’s some of the reasons why. There’re almost two million jobs in the sector, 100,000 companies. And, obviously, what a lot of communities like to hear is the average salary is anywhere from $75,000 to $150,000, depending on whether you’re looking at technicians or higher-end scientists or even more than that, of course. So, it’s a very high-impact industry.
It also involves a lot of research dollars, you know, almost $200 billion in 2019. And, of course, that’s increasing by tens of billions of dollars every year. So, it’s a global industry. It is an offshoot of different types of fields like biotechnology, pharmaceuticals, biomed, a lot of life system technologies. Maybe you’ve heard of things like nutraceuticals or even cosmeceuticals, food processing, environmental, certainly biomedical devices, and all kinds of issues around therapeutics and biologics.
And it’s all underpinned by a huge supply chain for the life science industry. So, think about stories of all those molecular elements, and biologics, and core blood or blood samples. So, it continues to be just a, you know, big economic driver here in the United States and across the globe.
Rick: Big driver, it is. Let’s follow up a little bit, kind of unpack that set of definitions a bit. Talk a little bit about how the growth of this industry from a job-creating standpoint. Because, you know, in a life science facility, there’s a lot of different…not everybody in there is a PhD scientist. There are a lot of different kinds of jobs associated with it. Do you have any comments on that?
Bob: Yeah. No. It’s a lot. It’s like the word “supply chain.” It’s a huge concept in that industry, different elements, different segments. This could get into agriculture, too. This can get into, obviously, the health care systems. This is about improving people’s lives and quality of life, and making sure that we improve the health, secure more sustainable food supply, promote cleaner energy, too. It all is linked to the life sc